36氪获悉，近期，睿健毅联医药科技（成都）有限公司（下称"睿健医药"）已完成一笔新的B+轮次融 资。本轮融资由北极光创投、创景资本、元希海河等机构共同投资，易凯资本任独家财务顾问。 本次募集资金将用于加速推进公司旗下帕金森病治疗产品NouvNeu001/NouvNeu003、眼科治疗产品 NouvSight001的临床研发，以及团队建设和产业化能力。 睿健医药成立于2017年，专注于小分子化学转录调控诱导多能干细胞（iPSC）产品开发。今年4月，睿 健医药就曾官宣一笔过亿元B+轮融资。公司的B轮次融资金额累计已超过3亿元。 睿健医药的核心产品NouvNeu001是一款化学诱导的功能型人源多巴胺能神经元前体细胞。此前完成 B+轮融资时，睿健医药创始人、CEO魏君曾对36氪介绍，该产品已启动多中心II期临床试验。此前的I 期临床中，NouvNeu001在移植15个月后的患者中"展现出了良好的安全性和耐受性"；同时，PET影像 分析也显示，随着移植时间增加，细胞在患者体内实现无免疫抑制剂状况下的长期存续。 创始人及投资人观点： 睿健医药创始人、CEO魏君表示，感谢新老投资人对睿健的信任和持续支持，也感谢易凯资本和睿 ...

Core Viewpoint - RuiJian Pharmaceutical has recently completed over 100 million yuan in Series B+ financing, led by Fengchuan Capital, to accelerate clinical trials and product development for its core pipeline targeting Parkinson's disease [4][5]. Financing and Growth - The company has raised over 200 million yuan in total from two rounds of Series B financing [5]. - RuiJian Pharmaceutical focuses on the development of small molecule chemical transcription regulation-induced pluripotent stem cell (iPSC) products since its establishment in 2017 [5]. Product Development and Clinical Trials - The core product NouvNeu001, aimed at treating Parkinson's disease, has recently entered Phase II clinical trials [5][6]. - Initial Phase I clinical results showed significant clinical improvement in motor functions and non-motor symptoms in patients after six months of cell transplantation [7]. - The product has demonstrated long-term efficacy, with some patients showing stable improvements in behavior and mobility beyond 60 weeks post-treatment [7]. Future Prospects and Regulatory Approvals - RuiJian Pharmaceutical is also developing NouvNeu003, targeting early-onset Parkinson's patients under 50, which has received approval for Phase I clinical trials [8]. - The company has made progress in overseas clinical research, with NouvNeu001's IND application approved in the U.S. and expected to start Phase I trials soon [8]. Market Position and Investor Insights - The founder and CEO, Dr. Wei Jun, emphasized the company's commitment to addressing clinical needs and providing innovative therapies that can potentially reverse disease progression [9]. - Investors express confidence in RuiJian Pharmaceutical's technology and its potential to become a leading player in the iPSC field, highlighting the significant social and commercial value of its products [10].